GHRP-6

GHRP-6 is a synthetic growth-hormone-releasing peptide that bodybuilding communities discuss especially for hunger. Some use that appetite wave to make bulking easier; others find it disruptive or feel no change. Hunger, scale weight and a GH pulse are different outcomes.

It prompts hormone release rather than supplying HGH. This six-amino-acid peptide stimulates GH release and activates the ghrelin receptor in laboratory work. Community talk connects it with appetite, recovery and body composition; that mechanism does not prove a physique benefit. Cabrales et al. — GHRP-6 pharmacokinetics in nine healthy men (Official context · Accessed 2026-09-30) · Bennett et al. — GHRP-6 activity at the ghrelin receptor (Official context · Accessed 2026-09-30)

The familiar community form is an injected peptide. Subcutaneous means under the skin. Logs discuss solo use and GHRH partners such as Mod GRF 1-29, often called CJC no-DAC, or sermorelin. Oral and nasal claims involve different exposure; injectable amounts cannot be carried across routes.

Source context — Cabrales et al. — GHRP-6 pharmacokinetics in nine healthy men: Nine men, single IV exposure at 100/200/400 mcg/kg; not subcutaneous gym exposure. Not efficacy, safe redosing, appetite-duration or drug-clearance proof. PubMed later intermittently returned only footer; ResearchGate author-copy supplied inspected text.

Source context — Bennett et al. — GHRP-6 activity at the ghrelin receptor: Primary laboratory research; abstract/captions inspected, not full text. Receptor activation does not establish a human benefit or appetite outcome. Allowed official_context category denotes supporting primary context, not an official endorsement.

Eating more is the clearest practical appeal. A Reddit poster describing about a month of use reported taking seconds and thirds at dinner. Their goal was appetite, not a demonstrated increase in muscle. Calories and training remain major confounders in bulk stories. Ghrp 6 and insulin sensitivity (Personal report · Accessed 2026-09-30)

No hunger is a real report, not an automatic dosing error. rageracing reported no appetite change at up to 300 mcg three times daily and after trying another product. Replies reported strong hunger and blamed product quality, but neither purity nor biological nonresponse was established. Ghrp6 and hunger (Community discussion · Accessed 2026-09-30)

Recovery and sleep reports involve several simultaneous changes. The original community record includes less soreness, deeper sleep, vivid dreams, fullness and multi-week size claims, often with a GHRH partner and surplus eating. Those reports do not establish recovery, fat loss, anti-aging or sustained IGF-1 benefits.

Source context — Ghrp 6 and insulin sensitivity: Self-report with no glucose results, hormone measurements or authenticated formulation. Reply offering a source has potential promotional influence; reassurance and berberine advice are not accepted medical evidence. Exact publication date left null because opened body shows relative dates.

Source context — Ghrp6 and hunger: Unverified products, GH co-use and bodybuilding cycle confounding. Site contains procurement/promotional discussion, excluded from article. Product swaps do not prove impurity or biological nonresponse.

100–300 mcg per subcutaneous administration; one to three daily administrations. These are preserved chart ranges, not validated dose targets. A 2022 Reddit discussion repeats 100 mcg up to three times daily; a separate 2026 appetite account reports 250–300 mcg total per day without specifying each administration. GHRP-6 protocol (Secondhand community claim · Accessed 2026-09-30) · Ghrp 6 and insulin sensitivity (Personal report · Accessed 2026-09-30)

Daily totals and individual amounts are different. The earlier record quotes roughly 200–900 mcg/day in multi-dose summaries, plus a separate 100 mcg once-daily bedtime chart for about one week. Three administrations of 100 mcg total 300 mcg/day. No loading phase was described.

Stack charts count each peptide separately. The preserved pairing is 100 mcg GHRP-6 plus 100 mcg Mod GRF per administration; variants list 100–150 mcg GHRP-6 plus 100–200 mcg Mod GRF, two or three times daily. Premixed vial ratios vary, so a combined amount does not identify either component.

About 1 mcg/kg per pulse is saturation lore. The inherited examples are 80 mcg at 80 kg and 100 mcg at 100 kg. They are not measured subcutaneous absorption ceilings or safety thresholds. Higher-amount charts include 100–200 mcg two or three times daily and 200–300 mcg per administration.

Escalation sheets are claims, not evidence of better results. The old record describes 100, 200 and 300 mcg three times daily across weeks 1–2, 3–4 and 5–12. It also warns of diminishing returns and more hunger or other effects. This ladder has no demonstrated superiority in the inspected evidence.

Source context — GHRP-6 protocol: OP is planning use, not reporting completed GHRP-6 results. Comment preference about prolactin cannot establish comparative endocrine safety. Original date not inferred from relative timestamps.

Source context — Ghrp 6 and insulin sensitivity: Self-report with no glucose results, hormone measurements or authenticated formulation. Reply offering a source has potential promotional influence; reassurance and berberine advice are not accepted medical evidence. Exact publication date left null because opened body shows relative dates.

Hunger reports range from minutes to about half an hour. Sulo describes stomach rumbling within 15 minutes; a 2026 Reddit account places use 10 minutes before dinner. The preserved record describes roughly 15–30 minutes. These accounts describe appetite, not a verified GH peak. GHRP 6 No hunger (Community discussion · Accessed 2026-09-30) · Ghrp 6 and insulin sensitivity (Personal report · Accessed 2026-09-30)

Hunger duration is separate from a half-life claim. The older community summary describes 30–60+ minutes; sota123's dated log describes about 90 minutes after a 20–30-minute onset. Neither is a measured clearance time. Just Started GHRP-6 (Personal report · Accessed 2026-09-30)

Longer benefit claims do not establish lasting change. Some logs describe appetite continuing during use, others expect it to fade. There is no reliable community estimate here for how long recovery, sleep or body-composition changes persist after stopping. GHRP-6 protocol (Secondhand community claim · Accessed 2026-09-30)

Twenty minutes circulates as a half-life claim. In a 2008 AnabolicMinds discussion, datBtrue repeats an older development-review statement about a 20-minute human in-vivo half-life. It supplies no subcutaneous measurement in that post. Half-life describes a falling measured amount, not how long hunger lasts. GHRP-6 Transdermal? (Secondhand community claim · Accessed 2026-09-30)

Distribution and elimination were measured separately. Cabrales studied nine healthy men after single IV amounts of 100, 200 or 400 mcg/kg. Mean distribution half-life was 7.6 ± 1.9 minutes; terminal elimination was 2.5 ± 1.1 hours. These research exposures do not establish subcutaneous hunger timing. Cabrales et al. — GHRP-6 pharmacokinetics in nine healthy men (Official context · Accessed 2026-09-30)

Source context — GHRP 6 No hunger: Anonymous uncontrolled reports on a site with source reviews/promotion. Hunger comparisons are individual; product-identity accusations and absorption claims are unverified.

Source context — Ghrp 6 and insulin sensitivity: Self-report with no glucose results, hormone measurements or authenticated formulation. Reply offering a source has potential promotional influence; reassurance and berberine advice are not accepted medical evidence. Exact publication date left null because opened body shows relative dates.

Source context — Just Started GHRP-6: One uncontrolled log, EQ/testosterone and later other interventions, diet and changing training. Post-workout dizziness has no established causal diagnosis; scale gain is not muscle verification.

Source context — GHRP-6 protocol: OP is planning use, not reporting completed GHRP-6 results. Comment preference about prolactin cannot establish comparative endocrine safety. Original date not inferred from relative timestamps.

Source context — GHRP-6 Transdermal?: Twenty-minute value is a quoted older review claim, not poster-measured subcutaneous kinetics. Original review not opened. Thread has major oral-dose arithmetic errors and unsupported absorption/desensitization certainty; those are not copied.

Source context — Cabrales et al. — GHRP-6 pharmacokinetics in nine healthy men: Nine men, single IV exposure at 100/200/400 mcg/kg; not subcutaneous gym exposure. Not efficacy, safe redosing, appetite-duration or drug-clearance proof. PubMed later intermittently returned only footer; ResearchGate author-copy supplied inspected text.

Different course lengths remain different claims. The preserved charts describe 4–6-week probes, 8–12-week blocks, and 12–16-week stacked bulk blocks, with 4–8 weeks off or an 8-on/8-off pattern. They do not establish the best course or a protective reset.

One forum account favors 6–8 weeks with about a week off. awm1981 also describes tiring of three daily injections. That personal preference differs from the longer chart patterns. Daily use and minority five-days-on/two-days-off schedules both remain in the old record. GHRP-6 cycle tips (Community opinion · Accessed 2026-09-30)

Switching peptides is not a demonstrated reset. The older discussion includes rotation to Ipamorelin or GHRP-2 and concern about continuous use beyond 16 weeks. Receptor-attenuation explanations and comparative rankings remain lore, not proof that rotation prevents harm.

Source context — GHRP-6 cycle tips: Commercially influenced bodybuilding forum with vendor/affiliate signatures and source-seeking OP. Duration is personal advice/preference, not an established course. Other-compound replacement suggestions not adopted.

The familiar community form is an injected peptide. Subcutaneous means under the skin. Logs discuss solo use and GHRH partners such as Mod GRF 1-29, often called CJC no-DAC, or sermorelin. Oral and nasal claims involve different exposure; injectable amounts cannot be carried across routes.

Stack charts count each peptide separately. The preserved pairing is 100 mcg GHRP-6 plus 100 mcg Mod GRF per administration; variants list 100–150 mcg GHRP-6 plus 100–200 mcg Mod GRF, two or three times daily. Premixed vial ratios vary, so a combined amount does not identify either component.

CJC with DAC + GHRP-6: Still sold and discussed for convenience / IGF-1 elevation lore; pulse purists often prefer no-DAC to keep short coordinated pulses. [community]

Premixed blend vials: Research products include fixed-ratio Mod GRF/GHRP-6 or CJC/GHRP-6 combinations. Composition varies by vendor, so the total vial amount does not identify each component's amount. [community]

Stacking makes both benefits and complaints harder to assign. The original record compares appetite-oriented GHRP-6 with GHRP-2, Ipamorelin, Hexarelin and oral MK-677. It includes MK-677 at 20–25 mg in evening stack talk and BPC/TB recovery stacks. These combinations do not isolate GHRP-6's contribution or prove a cleaner alternative.

The appetite effect can undermine a cut. The original community record treats ravenous hunger as useful during a bulk and disruptive during a calorie deficit. It also includes water retention, tight rings, hand tingling, headache, warmth, site irritation and lethargy; these are reported effects with uncertain frequency.

Dizziness and nausea also appear in actual logs. sota123 describes a short episode after a post-workout injection, then low energy and joint aches later. Concurrent hormones, diet and changing use prevent a causal diagnosis; an unpleasant sensation is not proof that GH release is working. Just Started GHRP-6 (Personal report · Accessed 2026-09-30)

Glucose and peptide-quality concerns have formal support. FDA flags possible cortisol effects, higher blood glucose through reduced insulin sensitivity, and immune-reaction risks associated with aggregation or impurities. Its GHRP-6 entry emphasizes limited safety information. Forum reassurance and suggestions to add berberine do not resolve those risks. FDA — compounding substances with potential significant safety risks (Official context · Accessed 2026-09-30) · Ghrp 6 and insulin sensitivity (Personal report · Accessed 2026-09-30)

Sport rules apply beyond competition day. WADA lists GHRP-6 in S2, prohibited at all times. A short claimed half-life is not a drug-testing clearance window. WADA — Prohibited List S2 (Official context · Accessed 2026-09-30)

Source context — Just Started GHRP-6: One uncontrolled log, EQ/testosterone and later other interventions, diet and changing training. Post-workout dizziness has no established causal diagnosis; scale gain is not muscle verification.

Source context — FDA — compounding substances with potential significant safety risks: Compounding safety context, not a blanket legal classification, quantified risk or personalized regimen. Only GHRP-6 entry supports this card; adverse reports for GHRP-2 or Ipamorelin are not transferred.

Source context — Ghrp 6 and insulin sensitivity: Self-report with no glucose results, hormone measurements or authenticated formulation. Reply offering a source has potential promotional influence; reassurance and berberine advice are not accepted medical evidence. Exact publication date left null because opened body shows relative dates.

Source context — WADA — Prohibited List S2: Current sport-rule context only; no detection time or universal possession-law inference.